Hitachi Chemical Co. America, Ltd.’s Acquisition of Caladrius Biosciences, Inc.’s TPC

Ambrogio Visconti

Paul Hastings LLP represented Caladrius Biosciences, Inc., (CLBS) a NASDAQ-listed clinical stage development company with a cell therapy pipeline focused on immune modulation and select cardiovascular…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here